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Vpx rescue of HIV-1 from the antiviral state in
mature dendritic cells is independent of the
intracellular deoxynucleotide concentration
Christian Reinhard1, Dario Bottinelli1, Baek Kim2 and Jeremy Luban1,3*
Abstract
Background: SIVMAC/HIV-2 Vpx recruits the CUL4A-DCAF1 E3 ubiquitin ligase complex to degrade the deoxynucleotide
hydrolase SAMHD1. This increases the concentration of deoxynucleotides available for reverse transcription in myeloid
cells and resting T cells. Accordingly, transduction of these cells by SIVMAC requires Vpx. Virus-like particles containing
SIVMAC Vpx (Vpx-VLPs) also increase the efficiency of HIV-1 transduction in these cells, and rescue transduction by HIV-1,
but not SIVMAC, in mature monocyte-derived dendritic cells (MDDCs). Differences in Vpx mechanism noted at that time,
along with recent data suggesting that SAMHD1 gains additional restriction capabilities in the presence of type I IFN
prompted further examination of the role of Vpx and SAMHD1 in HIV-1 transduction of mature MDDCs.
Results: When challenged with Vpx-VLPs, SAMHD1 was degraded in MDDCs even after cells had been matured with
LPS, though there was no increase in deoxynucleotide levels. Steady-state levels of HIV-1 late reverse transcription
products in mature MDDCs were increased to the same extent by either Vpx-VLPs or exogenous nucleosides. In
contrast, only Vpx-VLPs increased the levels of 2-LTR circles and proviral DNA in myeloid cells. These results
demonstrate that exogenous nucleosides and Vpx-VLPs both increase the levels of HIV-1 cDNA in myeloid cells, but
only Vpx-VLPs rescue 2-LTR circles and proviral DNA in myeloid cells with a previously established antiviral state. Finally,
since trans-acting Vpx-VLPs provide long-lasting rescue of HIV-1 vector transduction in the face of the antiviral state,
and exogenous nucleosides do not, exogenous nucleosides were used to achieve efficient transduction of MDDCs by
vectors that stably encode Vprs and Vpxs from a collection of primate lentiviruses. Vpr from SIVDEB or SIVMUS, Vpx from
SIVMAC251 or HIV-2, but not SIVRCM, degraded endogenous SAMHD1, increased steady-state levels of HIV-1 cDNA, and
rescued HIV-1 from the antiviral state in MDDCs.
Conclusion: Inhibition of deoxynucleotide hydrolysis by promoting SAMHD1 degradation is not the only mechanism
by which Vpx rescues HIV-1 in MDDCs from the antiviral state. Vpx has an additional effect on HIV-1 transduction of
these cells that occurs after completion of reverse transcription and acts independently of deoxynucleotide levels.
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Background
Viruses and their hosts apply selective pressure to each
other that influences how each evolves [1,2]. Viruses
evolve to escape detection and elimination by the host.
In response to changes in the virus there is selection for
variations in the host that minimize virus replication or
protect against virus-induced pathology. Essential steps
in the virus replication cycle in particular offer potential
targets for host-encoded viral inhibitors [3]. In the case
of retroviruses, reverse transcription of the viral genomic
RNA into cDNA, and integration of the viral cDNA into
the host cell chromosomal DNA, are essential steps in
the viral replication cycle that provide opportunity for
the cell to detect and inhibit the virus [4].
Retroviruses from the genus lentivirus, including HIV-1
and at least 40 different lineages of SIVs, infect non-
dividing cells such as resting CD4+ T cells and myeloid
cells. One hallmark of these non-dividing cell types is
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a concentration of deoxynucleotides (dNTPs) below the
threshold required for reverse transcription [5-8]. The cel-
lular enzyme SAMHD1 depletes the intracellular nucleotide
pool in non-cycling cells by converting deoxynucleotides
into deoxynucleosides and inorganic triphosphates [9]. This
depletion of the nucleotide pool inhibits reverse transcrip-
tion and thereby restricts infection by a range of retrovi-
ruses, as well as by some DNA viruses [10-12].
Some SIV lineages, including SIVSM, SIVMAC, SIVRCM,
SIVMND, as well as HIV-2, encode Vpx, an accessory
protein that counteracts SAMHD1 [13-17]. Vpx is not
encoded by HIV-1 but shares high similarity to Vpr from
which it probably arose by gene duplication [18] or re-
combination [19]. Though HIV-1 Vpr does not degrade
SAMHD1, Vpr from some viruses does have this activity,
indicating that the ability to degrade SAMHD1 arose
prior to the genesis of Vpx [20]. Like Vpr, Vpx is pack-
aged into the virion via the p6 region of the Gag poly-
protein [21,22] where it is required to infect myeloid
cells including monocytes, dendritic cells and macro-
phages [23-29]. Vpx is required for SIV replication in
sooty mangabeys, mandrills, and in macaques [30,31].
Via direct interaction with DCAF1, Vpx acts as an
adaptor that brings SAMHD1 to the CUL4A E3 ubiqui-
tin ligase complex [32,33]. The result is that SAMHD1 is
ubiquitinated and degraded by the proteasome [34].
SAMHD1 degradation is promoted by Vpx from SIVSM,
SIVRCM, and HIV-2, and by Vpr from SIVMUS and SIVDEB
[20]. The ability to degrade SAMHD1 is species-specific
and phylogenetic analysis indicates that the determinants
of the Vpr/Vpx interaction with SAMHD1 have been
subject to dynamic selective pressure. Vpx from HIV-2
and SIVMAC recognize the C–terminus of SAMHD1 while
Vpx from SIVMND2 and SIVRCM recognize the SAMHD1
N-terminus [35].
SAMHD1 is phosphorylated in cycling cells and dephos-
phorylated in IFN-stimulated myeloid cells and resting
CD4+ T cells [36,37]. Phosphorylation status does not
influence deoxynucleotide triphosphohydrolase activity
[36-39]. Phosphorylation-defective SAMHD1 mutants
retain HIV-1 restriction activity while phosphomimetic
mutants lack activity. This suggests that SAMHD1 blocks
HIV-1 infection via an additional mechanism that is inde-
pendent of effects on the nucleotide pool.
Vpx delivery to MDDCs or macrophages with virus like
particles (Vpx-VLPs) greatly enhances HIV-1 transduction
[40]. Additionally, we have shown in MDDCs [41], and
others have confirmed in macrophages [42,43], that Vpx
rescues HIV-1 from the antiviral state in IFN-treated
MDDCs. Interestingly, Vpx did not rescue SIVMAC or
HIV-2 from this antiviral state, and rescue was independ-
ent of Vpx binding to DCAF1 [41]. Here we extend these
findings by examining the role of SAMHD1 and by com-
paring the effect of Vpx-VLPs with the effect of exogenous
deoxynucleosides; the later intervention overcomes the
SAMHD1-mediated block to reverse transcription by in-
creasing the intracellular nucleotide pool. While exogen-
ous deoxynucleosides increased the yield of HIV-1 cDNA
in the presence of IFN, Vpx had an additional effect on
the level of 2-LTR circles and provirus in monocytes and
MDDCs.
Results
Vpx-VLPs and exogenous nucleosides rescue HIV-1 from
the antiviral state
We have previously shown that the Vpx proteins of
SIVMAC and HIV-2 rescue HIV-1 from the antiviral
state induced by type I IFN (IFNα/β) or pattern rec-
ognition receptor agonists such as LPS, poly(I:C) and
poly(dA:dT) [41]. Given that exogenous nucleosides
and Vpx-VLPs increase HIV-1 transduction of immature
macrophages to a comparable extent [11], the ability of
exogenous nucleosides and Vpx-VLPs to rescue HIV-1
transduction of mature MDDCs was compared.
MDDCs were stimulated for 18 hrs with 100 ng/ml
LPS to establish the antiviral state. Cells were then
treated with SIVMAC Vpx-VLPs produced from SIV3+
and codon optimized Vpx from SIVMAC251 expressed in
trans, to deliver Vpx into the cells, or treated with
2.5 mM deoxynucleosides, to increase the intracellular
dNTP pool [11]. After 2 hrs the MDDCs were then chal-
lenged with a single cycle HIV-1-GFP reporter virus
(NL4-3 GFP) pseudotyped with vesicular stomatitis virus
glycoprotein (VSV G).
When MDDC were treated with LPS, HIV-1 infection
was inhibited to levels below the detection limit (0.02%
GFP-positive cells; less than 10 GFP-positive cells in
100,000 cells assessed by flow cytometry) (Figure 1A).
Both Vpx-VLPs and nucleoside treatment increased
HIV-1 transduction roughly 100-fold above the level
of cells treated with SIVMAC VLPs lacking Vpx (ΔVpx-
VLPs) (Figure 1B); this was 7-fold above levels of imma-
ture MDDCs (no LPS) treated with ΔVpx-VLPs but it did
not completely rescue to levels of immature MDDC
treated with either Vpx-VLPs or nucleosides (Figure 1A).
In immature MDDC (the no LPS condition), Vpx-VLPs
and nucleosides increased HIV-1 transduction about 100-
fold when compared to immature cells treated with
ΔVpx-VLPs. Similar results were obtained in monocyte
derived macrophages (MDM) although LPS had a smaller
effect on HIV-1 restriction (data not shown). As expected,
when cells were treated with the proteasome inhibitor
MG132, the Vpx activity was reduced significantly
(74-fold) while a much smaller effect (3-fold) was ob-
served on the increased HIV-1 infection with exogenous
deoxynucleosides or ΔVpx-VLP treatment (Figure 1C).
To determine the role of SAMHD1 in HIV-1 restriction
in the presence of the antiviral state, SAMHD1 levels were
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reduced in MDDCs by transfecting siRNA targeting
SAMHD1 prior to LPS treatment (Figure 1D and 1E).
Knockdown of SAMHD1 led to a 7-fold increase in HIV-1
infectivity, which was completely rescued in the control
siRNA cells by adding Vpx-VLPs to the cells 2 hrs prior to
infection. In the presence of LPS, HIV-1 infectivity was
increased 5-fold by SAMHD1 knockdown. Surprisingly,
adding Vpx-VLPs rescued HIV-1 from LPS to the
same level of infectivity in the SAMHD1 knockdown
cells (8-fold) and in the control cells (40-fold) sug-
gesting that Vpx reduced SAMHD1 levels further
than the RNAi did or, alternatively, that Vpx over-
comes an additional block present in LPS-treated
MDDC.
Figure 1 VpxVLP, exogenous deoxynucleosides and SAMHD1 KD increase HIV-1 infection of MDDC. MDDCs were stimulated with
100 ng/ml LPS for 18 hrs or not (ctrl), then treated for 2 hrs with either 2.5 mM deoxynucleosides (dN), SIV Vpx-VLPs, or ΔVpx-VLPs, and finally
challenged with a VSV G pesudotyped HIV-1 reporter vector (NL4-3 GFP). 3 days later, > 0.5 x 105 out of 0.5 x 106 transduced cells were assessed
for GFP expression by flow cytometry, and the detection limit was set to 0.02% (<10 events). Data is displayed as percent GFP-positive cells (A) or
the higest dilution displayed as fold-change compared to the levels obtained with ΔVpx-VLPs (B). MDDCs were treated for 2 hrs with 1 μg/ml
MG132 or DMSO prior to addition of Vpx-VLPs or 2.5 mM deoxynucleosides and challenged with HIV-1 reporter vector 2 hrs later (C). 0.5 x 105
MDDCs were transfected twice with 20 nM siRNA targeting SAMHD1. 6 hrs after the second transfection cells were stimulated for 18 hrs with
100 ng/ml LPS. Cells were then treated for 2 hrs with Vpx-VLPs or ΔVpx-VLPs, challenged with NL4-3 GFP, and analyzed by FACS three days later
(D). 0.5 x 106 cells were harvested at the time of challenge with GFP-reporter virus to check SAMHD1 protein levels by western blot (E). All
experiments here were repeated on at least three separate occasions with similar results using cells from separate, random, healthy blood donors.
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Vpx degrades SAMHD1 in the presence of the antiviral
state but does not increase nucleotide levels
Vpx targets SAMHD1 for degradation by recruiting the
E3 ubiquitin ligase complex DCAF1-CUL4A [13,14]. The
Vpx Q76A mutant does not bind to DCAF1 and, in the
absence of an IFN-induced, antiviral state, this mutant
does not increase SIV or HIV-1 transduction efficiency in
myeloid cells [33,41].
To examine the effect of the Vpx Q76A mutant in the
context of the antiviral state, MDDC were stimulated with
LPS for 18 hrs and then treated for 24 hrs with SIV VLPs
containing Vpx or not. Induction of the antiviral state was
confirmed by the upregulation of MX1 (Figure 2A), a
protein strongly induced by type I IFN [44]. Wild type
Vpx reduced SAMHD1 protein levels while the Vpx
Q76A mutant did not reduce SAMHD1 protein levels
A B
C D
ctrl
LPS
E
G
F
Figure 2 Vpx degrades SAMHD1 in the presence of the antiviral state but does not increase nucleotide levels. MDDCs were stimulated
with 100 ng/ml LPS for 18 hrs and treated with SIVMAC VLPs containing Vpx, VpxQ76A or no Vpx (ΔVpx) for 24 hrs. 0.8 x 10
5 cells were harvested
for SAMHD1 western blot (A). SAMHD1 protein levels were measured and normalized to the actin signal. The ΔVpx sample was set to 100% (B).
2 x 106 were harvested for nucleotide extraction and measurement of intracellular deoxyadenosine concentration (C). 0.5 x 106 were challenged
with NL4-3 GFP after 2 hrs of VLP treatment in the presence of LPS (D) or absence (E) and 0.5 x 105 were assessed for GFP expression by flow
cytometry 3 days later. 1.6 x 106 cells were treated with either 1 μM MLN4924 or DMSO for 2 hrs prior to Vpx-VLPs or ΔVpx-VLPs addition. 24 hrs
later cells were harvested for SAMHD1 western blot (F) or deoxyadenosine concentration measurement for one sample per condition (G).
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(Figure 2A). SAMHD1 is upregulated in HeLa and HEK
293 cells by type I IFN ([45] and data not shown). There
was only a small increase of 20% in SAMHD1 levels by
LPS and protein levels were reduced to below 50% in
absence and presence of LPS (Figure 2B and Additional
file 1: Figure S1 and Additional file 2: Figure S2). The
reduction of SAMHD1 protein levels coincided with an
increase in intracellular deoxynucleotide levels as shown
by intracellular deoxyadenosine concentration (Figure 2B
and Additional file 1: Figure S1 and Additional file 2:
Figure S2). Nucleotide measurements were performed
in the linear range of the assay (4–128 fmol) and samples
were diluted if necessary. The volume of dendritic
cells to calculate the intracellular dNTP concentration
was determined to be 1000 μm3 as previously shown [46].
The detection threshold for the assay was determined to
be at 20 nM for dATP. Surprisingly, SAMHD1 protein
levels were reduced by Vpx in the presence of LPS, but
the nucleotide concentration remained at the level of
ΔVpx-VLPs and Vpx Q76A. The nucleotide concentration
in MDDCs was 20–40 nM, well below the HIV-1 RT Km
(>100 nM) [6,47]. Despite these low nucleotide levels, Vpx
and Vpx Q76A were still able to rescue HIV-1 from
the antiviral state 971-fold and 137-fold, respectively
(Figure 2D). In the absence of the antiviral state Vpx Q76
was not able to increase HIV-1 (Figure 2E).
CUL4A inhibitor MLN4924 blocks Vpx induced SAMHD1
A covalent modification by NEDD8 of CUL4A and other
cullin-RING E3 ligases (CRL) is required for their ubi-
quitin ligase activity [48]. The pharmacological inhibitor
MLN4924 inhibits the DCAF1-CUL4A E3 ligase com-
plex by blocking the NEDD8 activation enzyme (NAE).
It has been shown that MLN4924 inhibits the degradation
of APOBEC3G (A3G) by the HIV-1 accessory protein Vif,
which uses CUL5 to target A3G for proteasomal degrad-
ation [49]. MDDCs were treated for two hours with 1 μM
of MLN4924 and then Vpx-VLPs or ΔVpx-VLPs were
added. In the presence of MLN4924 Vpx was no longer
able to induce degradation of SAMHD1 (Figure 2E) and
nucleotide levels remained low in MLN4924 treated sam-
ples (Figure 2F). The same was observed using prote-
asome inhibitor MG132 (data not shown). Due to toxicity,
infectivity assays could not be performed in cells treated
with MLN4924 or MG132 in combination with LPS.
Exogenous nucleosides increase SIV infection but do not
rescue SIV from the antiviral state
By degrading SAMHD1, Vpx increases the available
nucleotide pool for reverse transcription which increases
the infectivity of a range of retroviruses [10]. We have
previously shown that while Vpx rescues HIV-1 100 to
1000-fold from the IFN-induced antiviral state, it does
not rescue SIVMAC transduction in this context [41]. To
compare the effect of exogenous deoxynucleosides on
SIVMAC and HIV-1, MDDCs were stimulated with 3 mM
deoxynucleosides for 2 hrs and then infected with an
HIV-1-GFP reporter vector or a SIVMAC-GFP reporter
vector, deleted for Vpx or not. All vectors were pseudo-
typed with VSV G and normalized for titer by titration on
HeLa cells.
Addition of exogenous deoxynucleosides increased the
infectivity of all three vectors from 4 to 6-fold (Figure 3A
and 3B), although, as expected, absolute infectivity
was lower for SIVΔVpx than for the other two viruses
(Figure 3A). To test if exogenous nucleosides rescued
SIVMAC from the antiviral state as effectively as they
rescued HIV-1, MDDC were stimulated with LPS for
18 hrs and then treated with nucleosides for 2 hrs prior to
infection with HIV-1 or SIVΔVpx. Nucleosides rescued
HIV-1 over 100-fold from the antiviral state but they did
not rescue SIVMAC (Figure 3C and 3D). We have previ-
ously shown that SIV expressing Vpx is not rescued by
from the antiviral state by Vpx-VLPs [41].
To determine if SAMHD1 degradation rescues SIV
from the antiviral state, SAMHD1 was knocked down
using shRNA. Monocytes were treated with Vpx-VLPs
after isolation from donor blood and transduced with a
lentiviral vector expressing a puromycin resistance cas-
sette and a shRNA targeting SAMHD1 in a miR-30 back-
bone [41,50,51]. After differentiation into MDDCs with
IL4 and GM-CSF, the cells were stimulated for 18 hrs with
LPS to induce an antiviral state and then challenged with
a SIV-GFP reporter vector expressing Vpx. Using Vpx-
VLPs to transduce monocytes with a knockdown vector
decreased SAMHD1 levels greatly (Figure 3E). Knock-
down of SAMHD1 increased SIV infectivity 4-fold in the
absence of LPS but, in the presence of LPS, SIV infection
could not be detected (Figure 3F). These results suggest
that SIV is blocked in cells in the antiviral state by a factor
different from SAMHD1 and not targetable by Vpx.
Vpx increases HIV-1 2-LTR circles in LPS-treated MDDCs
To compare the effect of exogenous deoxynucleosides
with the effect of Vpx on HIV-1 reverse transcripts and
metabolites, MDDC were stimulated with LPS for 18 hrs,
incubated with either Vpx-VLPs (Vpx) or 2.5 mM deoxy-
nucleosides alone (dN), or with the two in combination
(dN +Vpx), for 2 hrs and then infected with an VSV G-
pseudotyped, HIV-1-GFP reporter vector, or with a
control vector lacking the VSV G protein (ΔVSVg). After
24 hrs, low molecular weight DNA was harvested and
real-time PCR for full length HIV-1 cDNA (LRT) and
2-LTR-circles was performed. HIV-1 cDNA levels were
normalized to host cell mitochondrial DNA and com-
pared to cDNA levels from cells treated with ΔVpx-VLPs.
Exogenous deoxynucleosides, as well as Vpx-treatment,
increased LRT products 10-fold measured at 24 hrs
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(Figure 4A) as well as at 6 hrs (Figure 4E). There was
little variation among different donors, with the lowest
donor showing a 4-fold increase. In the absence of the
VSV G, or using a HIV-1-GFP reporter vector with the
reverse transcriptase active site mutation D185K/D186L,
LRT products were nearly undetectable (Figure 4A and
Figure 4F), indicating that PCR signals were not due to
carry-over of plasmid DNA from the transfection that
produced the vectors. In the absence of the antiviral state
both Vpx-VLPs treatment and exogenous nucleosides
increased LRT cDNA levels measured at 12 hrs post infec-
tion (Figure 4F).
2-LTR circles are used as a marker for nuclear import
of retroviral cDNA since they are believed to be created
Figure 3 Exogenous deoxynucleosides and SAMHD1 KD do not rescue SIV from the antiviral state. MDDCs were treated for 3 hrs with
3 mM deoxynucleosides (dN) and either challenged with a VSV G pseudotyped SIV-GFP reporter vector deleted for Vpx (SIVΔVpx) or not
(SIV Vpx+) or with an HIV-1-GFP reporter vector. The viruses were normalized by titration on HeLa cells. Values are displayed in %GFP positive cells
(A) or fold rescue by exogenous deoxynucleosides (B). MDDCs were stimulated with 100 ng/ml LPS for 18 hrs, treated with 2.5 mM deoxynucleosides
(dN) for 2 hrs and challenged with a SIVΔVpx or HIV-1 reporter vector. Values are displayed in %GFP positive cells (C) or fold-rescue by exogenous
deoxynucleosides (D). To achieve SAMHD1 knockdown, freshly isolated CD14+ monocytes were treated for 2 hrs with Vpx-VLPs and then transduced
with a lentiviral vector expressing shRNA targeting SAMHD1 (SAMHD1 KD) or luciferase (control KD) and differentiated into MDDCs over 5 days.
0.5 × 106 were used to assess knockdown efficency by western blot (E). Knockdown cells were stimulated with 100 ng/ml LPS and challenged with a
Vpx + SIV GFP reporter vector (SIVMAC239) (F).
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by end-to-end ligation of the two LTRs by cellular
enzymes in the nucleus. The level of 2-LTR circles was
measured using primers in which one anneals to the
2-LTR junction; this precludes detection of autointe-
gration events that are detected by primers flanking
the junction [52]. Treating MDDCs with deoxynucleosides
increased 2-LTR circles about 10-fold, as compared to
levels in cells treated with control VLPs that lack Vpx
(Figure 4B). Interestingly, treatment of cells with Vpx-
VLPs increased 2-LTR circles 40- to 70-fold. Unfor-
tunately, provirus was not detectable by Alu-PCR in
MDDCs that had been treated with LPS, even 72 hrs
after infection. As previously observed (Figure 1A)
infectivity levels did not differ after treatment with
either Vpx-VLPs or exogenous nucleosides alone or
in combination (Figure 4D). In the absence of the
antiviral state Vpx-VLPs treatment increased 2-LTR
circle formation 3-fold higher compared to exogenous
nucleosides (Figure 4F), indicating that this effect of
Vpx is also be observed to some extent in immature
DCs. This could explain the higher infectivity levels
observed in Figure 1A. These results show that Vpx-VLPs
Figure 4 Vpx increases HIV-1 2-LTR circles in LPS-treated MDDCs. 2 × 106 MDDCs were stimulated with 100 ng/ml LPS for 18 hrs, treated for
2 hrs with either ΔVpx-VLPs (ΔVpx) or Vpx-VLPs alone or combined with 2.5 mM deoxynucleosides (dN) and infected with NL4-3 GFP or NL4-3
GFP lacking VSV G protein (ΔVSVg) as negative control. 24 hrs later low molecular weight DNA was isolated and real-time PCR for full length
HIV-1 cDNA (LRT) (A) or 2-LTR circles (B) was performed and the ratio of fold change of 2-LTR circles over LTR was displayed (C). LRT and 2-LTR
circles were normalized to mitochondrial DNA and compared to ΔVpx levels. GFP positve cells were assessed for GFP expression by flow
cytometry after 72 hrs (D). MDDC from two donors were stimualted with 100 ng/ml LPS, treated with either ΔVpx-VLPs, Vpx-VLPs or 2.5 mM
deoxynucleosides and infected 3 hrs later. Low molecular DNA from single samples was isolated 6 hrs p.i. and real-time PCR for full length HIV-1
cDNA was prefromed (E). MDDC were treated with either ΔVpx-VLPs, Vpx-VLPs or 2.5 mM deoxynucleosides and infected 3 hrs later. Low molecular
DNA from single samples was isolated 12 hrs p.i. for real-time PCR for full length HIV-1 cDNA and 24 hrs p.i for 2-LTR cirlce real-time PCR (F).
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increase HIV-1 2-LTR circle formation in LPS-treated
MDDCs, an effect that was not observed in cells that were
treated with exogenous deoxynucleosides.
Vpx increases the HIV-1 provirus content in monocytes
Treatment of monocytes with Vpx-VLPs allows trans-
duction of these cells with lentiviral vectors and reporter
viruses [51]. To investigate the effect of exogenous deox-
ynucleosides on monocytes, freshly isolated CD14+ cells
were treated with either 2.5 mM deoxynucleosides (dN),
SIV Vpx-VLPs, or ΔVpx-VLPs over the entire duration
of the experiment. Protein samples for western blot ana-
lysis and cellular nucleotide extraction were taken before
treatment (0 hrs), at 3 hrs, two days (D2), and five days
(D5) after treatment with deoxynucleosides or VLPs.
Over the duration of the monocyte differentiation into
DCs, SAMHD1 levels increased considerably in the cells
treated with VLPs lacking Vpx or nucleosides while
SAMHD1 levels were nearly undetectable in cells treated
with Vpx-VLPs (Figure 5A). The intracellular nucleotide
Figure 5 Vpx increases HIV-1 provirus content in monocytes. Freshly isolated CD14+ monocytes from human peripheral blood were either
treated with ΔVpx-VLPs, Vpx-VLPs or 2.5 mM deoxynucleosides. 1 × 106 cells were harvested for western blot (A), 2 × 106 collected for nucleotide
measurement (B) and 0.5 × 106 were challenged 2 hrs after treatment with a HIV-1 reporter vector to assess GFP expression by flow cytometry
(C). Samples were collected before treatment (0 hrs), 3 hrs two days (D2) and five days (D5) after treatment. HIV-1 LRT (D) and 2-LTR circles (E)
were measured 3 days after infection and integrated provirus was analyzed by Alu-PCR at day 5 (F).
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concentration was increased 10-fold in cells treated with
Vpx-VLPs at day 2 after treatment and remained at the
same level also at day 5. Treatment with deoxynucleo-
sides led to a rapid increase in cellular nucleotide con-
centration already 3 hrs after treatment and increased
until day 5 (Figure 5B). Treatment with either Vpx-VLPs
or nucleosides increased infection with a HIV-1 GFP
reporter vector (Figure 5C). Vpx-VLP treatment in-
creased HIV-1 infection 3-fold more than nucleosides
(48% compared to 15% GFP-positive cells). LRT and 2-
LTR products were detected three days after infection.
LRT levels were very low but increased 5 and 7.5-fold
by Vpx-VLPs and exogenous nucleosides, respectively
(Figure 5D). 2-LTR circles were increased about 20-fold
by nucleosides while Vpx-VLP-treated samples showed an
80-fold increase compared to cells treated with ΔVpx-
VLPs (Figure 5E). This increase in 2-LTR circles was
associated with an increase in provirus. While nucleoside
treatment led to a 20-fold increase compared to ΔVpx-
VLPs treatment, Vpx-VLP-treatment increased provirus
levels 110-fold (Figure 5F). The increased provirus levels
were also reflected in an increase in mean fluorescence
intensity being 2.5–fold higher in the Vpx-VLPs treated
cells (Figure 6B). This is consistent with the finding above
that, relative to exogenous deoxynucleosides, Vpx-VLPs
increase the levels of provirus leading to the increased
expression of GFP, which results in the difference of MFI
measured (Figure 6B).
These results indicate that similar to MDDCs, deoxy-
nucleosides are able to overcome the SAMHD1 block to
reverse transcription and also increase 2-LTR circles
formation and provirus integration but Vpx-VLPs treat-
ment results in 4 to 5-fold higher 2-LTR circle and pro-
virus levels compared to nucleosides.
Transduction of MDDCs with lentivectors expressing SIV
Vpx or Vpr
To determine if Vpx and Vpr proteins encoded by differ-
ent SIVs have the capacity to degrade endogenous
SAMHD1 in MDDCs and to rescue HIV-1 from the
antiviral state in these cells, MDDCs were stably trans-
duced with lentivectors that express the different Vpx
and Vpr proteins. Since pre-treating monocytes with
Vpx-VLPs leads to a permanent decrease of SAMHD1
(Figure 5A), this approach could not be used to increase
transduction rate of HIV-1 vectors that stably express
these proteins. To test if treatment with exogenous
deoxynucleosides boosts monocyte transduction by len-
tiviral vectors, freshly isolated monocytes were treated
with either 2.5 mM deoxynucleosides or Vpx-VLPs for
2 hrs without removal over the duration of the differenti-
ation and transduced with a lentiviral vector encoding a
GFP cassette and a puromycin selection cassette under
the control of two independent promoters [53]. Although
treatment with exogenous nucleosides or Vpx-VLPs in-
creased MDDC transduction (Figure 6A) to similar levels
(62% vs. 85%) mean fluorescence intensity was 2.5–fold
higher in the Vpx-VLPs treated cells (Figure 6B). This is
consistent with the finding above that, relative to exo-
genous deoxynucleosides, Vpx-VLPs increase the levels of
provirus (Figure 5F).
Expression levels of lentivectors transduced in the
presence of exogenous nucleosides was not sufficient to
achieve knockdown of SAMHD1 or other genes, or to
detect Vpx protein after transduction with a lentiviral
vector encoding Vpx and a puromycin selection cassette
(data not shown). Yet, these transduction conditions
were sufficient to express vpx in MDDCs using a lenti-
viral vector encoding both Vpx and a puromycin selec-
tion cassette (Figure 6C). Nonetheless, in MDDCs
transduced with an SIVMAC vpx-expression vector and
treated with LPS, SAMHD1 was degraded and HIV-1
transduction was rescued 50-fold. As expected, Vpx
Q76A did not degrade SAMHD1 but still rescued HIV-1
7-fold from the antiviral state. Unlike the permanent
effect of Vpx-VLPs, the effect of deoxynucleosides used
for lentiviral vector transduction at the monocyte stage
disappeared after removing the cells from medium sup-
plemented with nucleosides (compare Figure 5B), since
HIV-1 was blocked by LPS and rescued 26-fold by re-
addition of deoxynucleosides.
The same approach was used to express Vpr encoded
by SIVDEB and SIVMUS, and Vpx from SIVRCM and HIV-2.
HIV-2ROD Vpx and both SIVDEB SIVMUS Vpr are reported
to be able to degrade human SAMHD1 [20] while SIVRCM
Vpx only degrades SAMHD1 from red capped mangabey.
As expected SIVRCM Vpx was not able to degrade human
SAMHD1 (Figure 6D) and was not able to rescue HIV-1
from the antiviral state. SIVDEB and SIVMUS Vpr on the
other hand were able to increase HIV-1 transduction
efficiency 45-fold in the face of an antiviral state. SIVMUS
Vpr almost completely degraded SAMHD1 while Vpr
from SIVDEB was less efficient. This might be due to
expression levels being lower for SIVDEB Vpr than for
SIVMUS when compared in transfected HEK 293 cells
with HA-tagged Vpr/Vpx (data not shown). Lower ex-
pression level might also explain why adding deoxynucleo-
sides increased HIV-1 transduction in the SIVDEB Vpr
cells while there was no additional effect observed in the
SIVMUS Vpr cells. Both Vpr from SIVDEB and SIVMUS
increased HIV-1 LRT compared to cells transduced with
the Vpx from SIVRCM of 23-fold and 7-fold, respectively.
Nucleosides further increased LRT product 190-fold in
SIVDEB Vpr and 54-fold in SIVMUS Vpr transduced cells
above SIVRCM Vpx levels without nucleosides. Vpx from
SIVMAC had the greatest effect on LRT levels (350-fold)
and nucleosides only a small effect (Figure 6E). Unexpect-
edly, Vpr from SIVDEB and SIVMUS only had a small effect
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on 2-LTR circle levels (3-fold increase) which was
enhanced further by the addition of deoxynucleosides.
SIVMAC Vpx led to an increase of 135-fold with no add-
itional effect of nucleosides, confirming the results from
Figure 4B. In the presence of SIVMAC Vpx 2-LTR circles
were increased 4-fold compared to cells expressing the
inactive Vpx from SIVRCM treated with exogenous nucleo-
sides. Although Vpr from SIVDEB and SIVMUS increased
HIV-1 LRT, only Vpx from SIVMAC was able to increase
2-LTR circles, indicating that this might be a conserved
function of the Vpx of the SIVSM/HIV-2 lineage.
Discussion
Exogenous deoxynucleosides and Vpx-VLPs both increase
the efficiency of HIV-1 transduction. At first glance,
both interventions appear to rescue HIV-1 via similar
A
E F
C D
B
LPS LPS
LPS LPS
Figure 6 Transduction of MDDCs with lentivectors expressing SIV Vpx or Vpr. Freshly isolated CD14+ monocytes from human peripheral
blood were treated with either Vpx-VLPs or 2.5 mM deoxynucleosides and transduced with a lentiviral vector expressing GFP. Cells were analyzed over
the course of differentiation (day 3 to day 6) for GFP expression by flow cytometry shown as percent GFP-postitve cells (A) or mean fluoresence
intensity (B). Monocytes were treated with 2.5 mM deoxynucleosides for 2 hrs and transduced with a lentiviral vector expressing a puromycin-resistance
cassette alone (−), or with the indicated SIVMAC Vpx WT or Vpx Q76A mutant (C), Vpr from SIVDEB (DEB), Vpr from SIVMUS (MUS), Vpx from HIV-2 (ROD),
Vpx from SIVRCM (RCM) or the empty vector (Vector) (D). Cells were selected with 1 μg/ml puromycin for 24 hrs at day 3 after transduction. After selection
cells were harvested, washed, re-plated and stimulated with 100 ng/ml LPS for 18 hrs. Cells were treated or not with 2.5 mM deoxynucleosides for 2 hrs
and challenged with HIV-1-GFP reporter vector. GFP positve cells were assessed for GFP expression by flow cytometry 72 hrs later. Low molecular weight
DNA was collected at 24 hrs after challenge and LRT (E) and 2 LTR circles (F) were measured by qPCR.
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mechanisms. Exogenous deoxynucleotides are taken up by
DCs and this presumably replenishes the dNTPs that
are maintained at low level by SAMHD1 in these cells
(Figure 5B). Vpx-VLPs degrade SAMHD1 and thereby
prevent dNTP hydrolysis. In the context of a type I IFN-
mediated antiviral state in MDDCs, though, this is not the
only mode of action by which Vpx rescues HIV-1. We
have previously shown that Vpx is able to rescue HIV-1
but not SIVMAC or HIV-2 from the antiviral state induced
by type I IFN itself (IFNα/β) or PRR agonists such as LPS,
poly(I:C) and polydAdT [41]. Here we extend these find-
ings to the HIV-1 restriction factor SAMHD1.
SAMHD1 restricts HIV-1 replication in resting CD4+ T
cells [16,17] and myeloid cells [13-15] by depleting the
intracellular nucleotide pool [11]. The nucleotide concen-
tration in macrophages is 20 to 40 nM, well below the
HIV-1 RT Km of >100 nM, and orders of magnitude lower
than the 2 to 5 μM measured in cycling CD4+ T cells
[6,47]. Dendritic cells have levels similar to those of mac-
rophages (Figure 2B) and these levels do not change upon
LPS stimulation [45]. As shown by others in macro-
phages [11,42,43], and here by us in DCs (Figure 1A
and Figure 3C) and monocytes (Figure 5), addition of
exogenous deoxynucleosides artificially increases the
intracellular deoxynucleotide pool, allowing HIV-1 reverse
transcription to take place [11].
It has been reported that in macrophages Vpx does not
rescue HIV-1 from IFNα treatment despite SAMHD1
degradation and increased nucleotide levels [42,43]. In
these reports Vpx-VLPs or the addition of exogenous
deoxynucleosides increased HIV-1 infectivity to the level
seen with no Vpx treatment in the absence of the antiviral
state. In DCs we observed an increase of HIV-1 infection
in absence and presence of the antiviral state of about
100-fold (Figure 1A and Figure 1B) which coincides with
Vpx and nucleoside having a similar effect on HIV-1 full
length cDNA (LRT) of about 10-fold increase (Figure 4A)
in the presence of the antiviral state as well as in the
absence (Figure 4F) and [5,45]. When cells were treated
with LPS neither deoxynucleosides nor Vpx-VLPs were
able to fully rescue HIV-1 infectivity to the level of Vpx
and deoxynucleosides without LPS indicating that there is
indeed a Vpx- and SAMHD1-independent factor upregu-
lated in the antiviral state.
While in type I IFN stimulated macrophages SAMHD1
degradation led to an increase in intracellular deoxynu-
cleotide levels [42,43], this was not observed in MDDCs
(Figure 2A). It has been shown that SAMHD1 is protected
from Vpx mediated degradation in primary myeloid and
plasmacytoid dendritic cells [54] and in type I IFN treated
THP-1 cells [43]. Although we see a small increase in
SAMHD1 levels in LPS treated MDDCs, SAMHD1 is
degraded to similar levels in the presence of the anti-
viral state (Figure 2B and Additional file 1: Figure S1
and Additional file 2: Figure S2). This could indicate that
the regulation of the intracellular deoxynucleotide con-
centration in MDDCs occurs at multiple levels and
results from a balance of deoxynucleotide degradation
by SAMHD1 and newly produced deoxynucleotides
by such enzymes as ribonucleotide reductase [55].
Interestingly, as we have previously reported, Vpx does
not rescue SIVMAC or HIV-2 from the antiviral state in
MDDCs. The factor blocking SIV in MDDCs in the anti-
viral state is independent of SAMHD1 and independent
of Vpx (Figure 3) since neither SAMHD1 knockdown,
nor addition of exogenous nucleosides, nor Vpx-VLPs
were able to rescue SIV from LPS [10,38]. It could be
that the factor that flattens SIVMAC in MDDCs in the
antiviral state is the same factor that inhibits HIV-1.
SAMHD1 knockdown in MDDCs using siRNA increa-
sed HIV-1 levels in the absence of LPS and also, to a
smaller extent, in the presence of LPS. SAMHD1 knock-
down in THP-1 cells is reported to increase HIV-1
infectivity by boosting intracellular dNTP levels [11]. In
MDDCs, Vpx-VLPs increased HIV-1 infectivity even
after SAMHD1 knockdown (Figure 1D). This could be
because Vpx decreases SAMHD1 levels beyond that of
the knockdown which would then further increase the
dNTP pool. Alternatively, Vpx-VLPs might remove an
additional block present in LPS-treated MDDCs that
acts independently of nucleotide levels. The latter expla-
nation is supported by the observation that, despite
SAMD1 degradation and a 100-fold rescue of HIV-1
infectivity, there was no increase in nucleotide levels by
Vpx-VLPs in LPS-treated MDDCs (Figure 2B).
Our findings are in accord with recent reports that the
constitutive deoxynucleotide triphosphorylase activity of
SAMHD1 is distinct from its retroviral restriction activity,
which is regulated by phosphorylation [36-38]. SAMHD1
is phosphorylated at threonine 592 in dividing, HIV-1
permissive cells, such as activated T cells or cycling
THP-1 cells. SAMHD1 is dephosphorylated in HIV-1
non-permissive cells such as PMA-arrested THP-1 cells
or monocytes. In macrophages and MDDCs a portion of
SAMHD1 is phosphorylated, and this residual phosphor-
ylation disappears with type I IFN treatment, suggesting
the presence of an IFN-inducible phosphatase. Vpx
degrades SAMHD1 independent of its phosphorylation
status [36].
The block to HIV-1 reverse transcription that results
from SAMHD1-mediated depletion of dNTP can be over-
come by either Vpx-VLPs or by exogenous nucleosides.
This was shown by the fact that both Vpx and exogenous
deoxynucleosides increase HIV-1 cDNA (Figure 4A). But
there was an additional block in LPS-treated myeloid cells,
at the level of 2-LTR circles and provirus establish-
ment that was overcome by Vpx-VLPs, but not by
exogenous deoxynucleosides (Figure 4B). Vpx-VLPs, but
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not exogenous deoxynucleosides, remove SAMHD1
(Figures 2A and 6C), which is de-phosphorylated in
MDDCs under these conditions [36]. The post-reverse
transcription block that occurs with LPS treatment might
be due to SAMHD1 and its recently described ability to
bind HIV-1 cDNA and to cleave single-stranded RNA and
DNA [56]. Despite the fact that exogenous nucleosides
had a greater effect on cellular nucleotide levels than did
Vpx-VLPs in monocytes (Figure 5B), Vpx increased HIV-1
infection to higher levels than did exogenous deoxy-
nucleosides (Figure 5C). This increase in infectivity corre-
lated with the fact that Vpx-VLPs increased 2-LTR circle
levels 4-fold higher, and provirus levels 5-fold higher, than
with nucleosides (Figure 5E and Figure 5F).
We and others have used Vpx-VLPs to achieve lentiviral
transduction levels sufficient to knockdown genes in
MDDCs [41,50,51,57]. While this technique works well, it
has to be considered that monocytes treated with Vpx-
VLPs still do not express SAMHD1 5 days after diffe-
rentiation into MDDCs (Figure 5A). Treating monocytes
with deoxynucleosides did not change SAMHD1 levels
(Figure 5A) but this permits lentiviral vector transduction,
although at a lower level than when monocytes are treated
with Vpx-VLPs. Using exogenous deoxynucleosides, Vpx
and the Q76A Vpx mutant were expressed from within
MDDCs, without prior degradation of SAMHD1 by Vpx-
VLPs. As expected the Vpx Q76A mutant was unable to
degrade SAMHD1 and it failed to increase dNTP levels
(Figures 2B and 6C). Nonetheless, Vpx Q76A was able
rescue HIV-1 from the antiviral state (Figure 6C), indicat-
ing yet again that the boost to HIV-1 infectivity is not all
due to effects on deoxynucleotide levels.
SAMHD1 dNTP depletion activity requires tetrame-
rization [58]. Binding of Vpx to SAMHD1, and subse-
quent recruitment of the CUL4A-DCAF complex disrupts
SAMHD1 activity before its degradation by the prote-
asome [59]. Given these observations, and data presented
here (Figure 2A-D) and previously [41], our data are con-
sistent with a model in which the Vpx Q76A mutant
retains the ability to bind to SAMHD1, but the mutant
does not interact with DCAF1 and therefore does not
recruit CUL4A. SAMHD1 is therefore not degraded, but
the mutant Vpx might still interfere with SAMHD1 oligo-
merization. This would explain how the mutant could
have no effect on dNTP levels yet still provide significant
rescue of HIV-1 transduction in LPS-treated MDDCs.
Another possibility is that there is an additional block to
HIV-1 in LPS-treated MDDCs that is altogether inde-
pendent of SAMHD1 and the DCAF1-CUL4A complex.
The Vprs encoded by SIVDEB and SIVMUS have been
reported to degrade SAMHD1 from certain species,
including human SAMHD1 [20]. Vpx from HIV-2 or
SIVMAC, and Vpr from SIVMUS, each recognize the
C-terminus of SAMHD1, while Vpx from SIVMND2 and
SIVRCM recognize the N-terminus of SAMHD1. Vpr
from SIVDEB recognizes both the C- and N-termini of
SAMHD1 and thus targets the broadest range of
SAMHD1 orthologues [35]. Here we exploited the increa-
sed lentivector transduction with exogenous deoxynucleo-
sides to show for the first time that these Vpr proteins are
able to degrade endogenous human SAMHD1 in MDDCs
and increase the levels of HIV-1 cDNA and infectivity.
Compared to Vpx from SIVMAC, Vpr from SIVMUS and
SIVDEB do not increase HIV-1 2-LTR levels suggesting
that Vpx from the SIVSM/HIV-2 lineage might possess an
additional activity which is not conserved in all SIV
Vpr/Vpx genes able to degrade SAMHD1.
Conclusions
Here we showed that Vpx removes SAMHD1 protein
and rescues HIV-1 transduction from the antiviral state
in LPS-treated MDDCs, largely independently of effects
on intracellular deoxynucleotide levels. Vpx increases
the level of 2-LTR circles and provirus in myeloid cells,
an effect which was not observed by artificially increas-
ing the intracellular nucleotide pool with exogenous
nucleosides.
Methods
Ethics statement
Buffy-coats obtained from anonymous blood donors
were provided by the Blood Transfusion Center of the
Hematology Service of the University Hospital of Geneva
by agreement with the service, after approval of our
project by the Ethics Committee of the University
Hospital of Geneva (Ref #0704).
Cell lines, primary cells, cytokines, and tissue culture
HEK 293 cells were provided by Dr. Walter Mothes
(Yale University) and HEK 293FT cells were obtained
from Invitrogen. HEK 293, HeLa, and HEK 293FT
cells were grown in Dulbecco’s modified Eagle medium
(D-MEM) (high glucose) with 10% FBS (PAA), 20 mM
L-glutamine, and 1000 mg/ml Penicillin-Streptomycin
(Invitrogen).
Peripheral blood mononuclear cells (PBMC) were
isolated from healthy donor buffy coats using Ficoll-
Paque Plus (GE Healthcare). CD14+ monocytes were
enriched from PBMC by positive selection using CD14
MicroBeads following the manufacturer’s protocol
(Miltenyi Biotec). Enrichment was routinely verified
to be greater than 95% using phycoerythrin (PE)-conjugated
monoclonal antibodies against CD14. CD14+-enriched cell
populations were counted, centrifuged at 200 × g for
10 min, and resuspended at 2 × 106 cells/ml in RPMI-1640
supplemented with 10% FBS (Hyclone), 1× MEM NEAA,
20 mM L-glutamine, 25 mM HEPES, 1000 mg/ml peni-
cillin-streptomycin, 1 mM sodium-pyruvate and 50 μM
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β-Mercaptoethanol (all from GIBCO). To induce differen-
tiation of monocytes into dendritic cells (MDDCs), recom-
binant human granulocyte-macrophage colony-stimulating
factor (GM-CSF) and recombinant human interleukin 4
(IL-4) conditioned medium was added at a dilution of
1:50 and cells were cultured for 5 days at 37°C in 5% CO2.
Cytokine-conditioned medium was produced in HEK
293 cells transduced with a lentiviral vector pAIP (see
below), encoding either GM-CSF or IL-4, and puro-
mycin acetyltransferase. After two weeks of selection in
10 μg/ml puromycin transduced cells were incubated for
two weeks in complete RPMI-1640 to allow secretion
and accumulation of cytokines in the medium. The
activity of the cytokines was tested by comparing the
conditioned medium to commercially available GM-CSF,
used at a final concentration of 50 ng/ml, and IL-4, used
at a final concentration of 25 ng/ml, (both from R&D
Systems). The phenotype and response to pattern recog-
nition receptors and IFNβ of differentiated MDDC was
tested using fluorescein isothiocyanate (FITC)-conjugated
monoclonal antibodies against CD1a and CD86, phyco-
erythrin (PE)-conjugated monoclonal antibodies against
CD14 and CD80, and allophycocyanin (APC)-conjugated
monoclonal antibodies against CD209 (DC-SIGN) and
CD83 (all from Miltenyi Biotec).
Opti-MEM® I Reduced Serum Media was purchased
from Invitrogen and used to dilute DNA for transfec-
tion. Ultrapure, E. coli K12 LPS was obtained from Invi-
vogen. Recombinant, human IFN-β was obtained from
PBL InterferonSource. Deoxynucleosides were purchased
from Sigma-Aldrich (2′deoxyguanosine monohydrate,
cat# D0901; thymidine, cat# T1895; 2′deoxyadenosine
monohydrate, cat# D8668; 2′deoxycytidine hydrochlor-
ide, cat# D0776). A 100 mM stock solution was prepared
by dissolving each of the four nucleotides at 100 mM in
RPMI 1640 by heating the medium at 80°C for 15 min.
If not state otherwise exogenous nucleosides were
added to the cells diluted in the appropriate medium
2 hrs before reporter vector addition. CUL4A inhibi-
tor MLN4924 was purchased from Active Biochem
and proteasome inhibitor MG132 was purchased from
Sigma-Aldrich.
Plasmid DNAs
Vpx from HIV-2 ROD and Vpx from SIVMAC251 Vpx
was codon optimized through services provided by Slon-
ing Biotechnologies GmbH (Puchheim, Germany) and
Microsynth AG (Balgach, Switzerland) and the glutam-
ine to alanine mutation at position 76 was introduced as
described [41]. SIV Vpr from De Brazza’s monkey (SIVDEB
CM5 Vpr (AY523866)), mustached monkey (SIVMUS1
CM1239 (EF070330)) and SIV Vpx from red-capped
mangabeys (SIVRCM Vpx (AAM34564.1)) were codon op-
timized by Genecust and cloned into empty pcDNA3.1(−)
or a version expressing a N-terminal triple HA-tag using
5′ XbaI and 3′ NotI sites. DNA sequences are provided in
Table 1.
The following virus plasmids and vectors were used in
this study: pWPTs-GFP is an HIV-1-based transfer
vector with EGFP expression under the control of the
EF1α promoter used in Figures 3A and 3B and 4F [60].
psPAX2, an HIV-1 gag-pol expression plasmid, and
pMD2-G, a vesicular stomatitis virus G protein expres-
sion plasmid, were generous gifts from Didier Trono
(Ecole Polytechnique Fédérale de Lausanne, Lausanne,
Switzerland). 8.9NdSB is a minimal HIV-1 packaging
plasmid used in Figure 3A and 3B [61]. pNL4-3-GFP is
pNL4-3 with an env-inactivating mutation and GFP cod-
ing sequence in place of nef and used if not stated other-
wise [62]. SIV3+ is an SIVmac251 gag-pol expression
plasmid that also encodes Vpx, Vpr, and Vif used in
Figure 3A and 3C [63]. SIV3+ ΔVpx was generated by
digestion with BstB1 and religation after blunting ends
with DNA Polymerase I, Large (Klenow) Fragment (New
England BioLabs); this introduces a nonsense codon in
place of Vpx amino acid 25. SIVMAC239env
–GFP was
used in Figure 3F and is described elsewhere [64] as well
as psGAE used in Figure 3A and 3C [65], an SIVMAC
transfer vector expressing GFP, in which the cyto-
megalovirus (CMV) promoter was replaced with the
spleen focus-forming virus (SFFV) LTR. pAPM is an
HIV-1 based knockdown vector in which a single tran-
script driven by the SFFV LTR contains a miR30 frame-
work modified to target a gene of interest and the
puromycin N-acetyltransferase gene [50]. pAIP is an
HIV-1-based transfer vector expressing the protein of
interest from the SFFV LTR followed by the encephalo-
myocarditis virus (EMCV) internal ribosome entry site
(IRES) cassette and the puromycin resistance cassette
[66].
Reporter vector and virus like particle production
Lentiviral vectors were produced by transfecting 293FT
cells using Lipofectamin according to the protocol from
the manufacturer (Invitrogen). For three part vector sys-
tems, the following DNA ratio was used: 4 parts transfer
vector: 3 parts gag-pol expression plasmid: 1 part VSV-G
expression plasmid. For two part virus systems a 7:1 ra-
tio was used (7 parts env– virus: 1 part pMD2.G). Virus
like particles (VLP) were produced at a ratio of 5 parts
pSIV3+ ΔVpx: 2 parts of Vpx expressing plasmid, and 1
part VSV-G expression plasmid. Viruses, vectors and
VLP stocks were normalized by single cycle infectivity
assay on HEK-293 or HeLa cells and by measuring the
reverse transcriptase activity in the viral supernatant by
qRT-PCR [67]. All supernatants were filtered through a
0.45 μm filter. For infections, virus stock was diluted in
the appropriate cell culture medium and added to the
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cells. Vpx-VLPs were produced in the same manner and
where added if not stated otherwise 2 hrs before addition
of the reporter vectors used.
RNAi and transgene expression in MDDCs
Knock down vectors targeting SAMHD1 were cloned as
described previously [50]. Briefly, three 97-mer oligo-
nucleotides (Table 2) were synthesized and PAGE puri-
fied by Microsynth AG (Balgach, Switzerland). Target
sequences were cloned into pAPM using EcoRI and XhoI
sites. The sequences were tested in HEK cells and ts 2
was determined by western blot analysis to be the most
efficient in knocking down SAMHD1 and used in further
experiments. To obtain knockdown in MDDC, CD14+
cells, freshly isolated from PBMC as described above, were
treated with SIVMAC-251 VLP for 2 h, and then trans-
duced with either a control or experimental pAPM
microRNA-based shRNA vectors [41,50,51]. The CD14+
cells were then allowed to differentiate into MDDC. After
differentiation, the MDDC were selected with 10 μg/ml
puromycin for 24 h and assayed for protein knock down
by western blot. Transduction efficiency was tested and
determined to be greater than 90% of transduced MDDC
using pAGM, a vector expressing EGFP in place of
the puromycin selection cassette. For transient siRNA
transfection targeting SAMHD1 in MDDC, 5 × 105
MDDC were plated in a 12-well plate in 600 μl culture
medium. 20 nM of siSAMHD1 ts2 (5′-CAACCAGAG
CUGCAGAUAA-3′) (kindly provided by Dr. Nadine
Laguette, CNRS Montpellier) were complexed with 6 μl of
HiPerFect Transfection Reagent (Qiagen), following the
manufacturer’s instructions and added to the MDDC
culture. A second round of transfection was performed
24 hours later. Protein knock down was assessed by west-
ern blot 24 hours after the second round of transfection
[68]. To over express codon optimized SIV Vpr and Vpx
in MDDC the genes were cloned 5′ XbaI to 3′ NotI into a
lentiviral vector (pscALPS) expressing the gene of interest
under the control of the SFFV LTR and puromcyine selec-
tion cassette under the control of the CypA promoter.
Freshly isolated CD14+ monocytes were treated with
2.5 mM deoxynucleoside mix (1.25 mM deoxyguanosine)
for 2 hr and then freshly produced lentiviral vector super-
natant was added in a 1:2 ratio. The cells were then
allowed to differentiate into MDDC for 4 days and se-
lected with 1 μg/ml puromycine for 24 hours. At day 5 of
differentiation the cells were harvested and the deoxy-
nucleosides were washed away with PBS before the
cells were reseeded into 24 well plates for downstream
experiments.
Table 1 Codon optimized Vpx and Vpr sequences
Accessory gene Codon-optimized nucleic acid sequence
SIVMAC-251 Vpx atgagcgacccaagagaaagaatcccacctggaaatagcggcgaagaaactattggagaggctttcgagtggctgaatagaaccg
tggaggagataaatagagaagctgtgaaccatctgcccagagagctgatcttccaagtgtggcaaaggagctgggagtattggca
cgacgagcagggcatgtcccagagctatgtgaaatatagatatctgtgtctgatgcagaaggcactgttcatgcactgtaaaaaggg
ctgtaggtgcctcggggaaggacatggggccggcggatggaggcccggcccacctcctccccctccccccggcctcgcatga
HIV-2ROD Vpx atgacagatccacgagagaccgtacccccaggcaacagtggagaagaaaccattggcgaggcgttcgcatggctcaacaggacg
gtggaggccatcaacagagaagccgtaaatcacctgcccagggaacttatctttcaggtctggcagaggagctggcggtactggca
cgacgagcagggcatgtctgagagctataccaaataccgctacctttgtatcatccagaaggccgtttacatgcacgtgagaaaagg
atgtacatgcttgggaagaggtcacggccctggcggctggagacctggcccaccaccccctcccccacctgggctggtgtga
SIVRCM Vpx atggctgagcgggcaccagaagtgccaactggcgccggcgaggccgagtttcagccctggctccgggacatgttggagaaagtc
aacctggaggcccggttgcacttccaccccgaattcatctttaggctgtggagaacatgcgtcgagcactggcatgatgtgcaccag
aggtccctggagtacgccgcctataggtacctcctcctgatgcagaaggccctgttcattcactgccagaccgggtgtagccaaaga
catgggcccaatcctagggctgtgggagagcgcattacaatcctgcctgggatgtga
SIVMUS1CM1239 Vpr atggagagggtgcccccatcacatcggcccccatggcactccagggtggtcccaactaccatgcagcaggcacagcaggctatgtg
ggacctgaacgaggaagccgagaagcacttcagcagagaggagctgcggggaatctggaacgatgtcaccgagctccccgccga
tcccaactggaccgtggatcaggccgctattgcctgtgccattgattacattcggcggactcagacactcctgtttcggcactacaggg
aaggctgctatcaccggtacagcaacacaatccgcaggtaccctaacatcagacccttgcgcgggacacaagcccctcccagtaacag
catgccaaatgccgaccctacacctccccttagaccctctaggtacaggatggacgagtga
SIVDEBCM5 Vpr atggagcgctatcctcctagtcatcccccacatttcacatccagaactgtcccaatgacccggctggcactgcagcaggccatgcagga
cctgaacgaggaggccctgaagcacttcaccagggaagagttgtggggggtgtggaaccactgtgtcgatttgcccgcccagcccg
attggacaggagagcaggcctgggccgctagcgtgatcgattacattaaaatcgtgcaaaggatgctctggctccaccttagggagg
cttgctttcaccgggagagagaggccacacggcggtaccccaacattaggccactgaccggccggaatagggaggtgagagacg
gggaatga
Table 2 shRNA SAMHD1 knockdown target sequences
SAMHD1 shRNA target sequences
TS1 5′TGCTGTTGACAGTGAGCGCGCTTCCTTTATGAGATAGTATTA
GTGAAGCCACAGATGTAATACTATCTCATAAAGGAAGCTTGC
CTACTGCCTCGGA-3′
TS2 5′TGCTGTTGACAGTGAGCGCGCTGATTCGAGTATATTGTAATA
GTGAAGCCACAGATGTATTACAATATACTCGAATCAGCTTGCC
TACTGCCTCGGA-3′
TS3 5′TGCTGTTGACAGTGAGCGCGCCATCATCTTGGAATCCAAATA
GTGAAGCCACAGATGTATTTGGATTCCAAGATGATGGCATGC
CTACTGCCTCGGA-3′
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Real-time PCR for late RT, 2-LTR circles and integrated
provirus
Low molecular weight DNA was extracted from 1 to
2×106 MDDC using the DNA Blood and Tissue Kit from
Qiagen. Quantitative PCR for NL4-3GFP (two part
vector) or pWPTs (three part vector) late RT (full length
HIV-1 cDNA, LRT) and 2-LTR circles overlapping the
junction were detected with SYBRgreen (Invitrogen) or
TaqMan probes as described here [52] 6 hours and
24 hours post infection, respectively. Primers to detect
pWPTs-GFP LRT product using SYBRgreen was pWPTS
J1B fwd and J2 rev (Table 3). Primers to detect 2-LTR
circles overlapping the perfect junction for both pNL4-
3-GFP and pWPTs-GFP using SYBRgreen were Junct2
fwd coupled with J2 rev. LRT products from pNL4-3-GFP
were detected with the TaqMan system using the primers
J1 fwd and J2 rev with the Late RT probe (LRT-P). 2-LTR
circles overlapping the junction from pNL4-3-GFP were
detected using the TaqMan sytem (Table 4) using the
primers MH535 (fwd) and MH536 (rev) [69]. The Taq-
Man probes overlapping with the junction was JunctPro
[52]. Integrated provirus of pNL4-3-GFP was detected
with the TaqMan system using the Alu PCR primers
MH535 (fwd), SB704 (rev) and MH603 probe [69].
Mitochondrial DNA was used for normalization with
the following primer/probe set: Mito fwd (MH533),
Mito rev (MH534), Mito probe [69]. SYBRgreen 2-LTR
circle and LRT PCR reaction contained 1×SYBR green
mix (10 mM Tris pH 8.3, 10 mM KCl, 2.5 mM NH4SO4,
5 mM MgCl2, 0.1 mg/ml BSA, 0.2 mM dNTPs, 1× SYBR-
green (Milford)), 300 nM each primer, 6 μl of template
low-molecular weight DNA (100 to 250 ng total), and
0.1 μl of Hot Start Taq Polymerase (Promega) in a volume
of 20 μl. After initial incubation at 95°C for 2 min to acti-
vate the Hot Start Taq Polymerase, 40 cycles of amplifica-
tion and acquisition were carried out at 95°C for 6 s,
followed by 10 s at 55°C, 30 s at 72°C and 6 s at 80°C. Taq-
Man 2-LTR circle PCR and LRT reaction mix contained
1× TaqMan Universal Master Mix (Applied Biosystems),
50 nM each primer, 100 nM TaqMan probe and 6 μl of
template low-molecular weight DNA (100 to 250 ng total)
in a volume of 20 μl. After an initial incubation at 95°C for
10 min, 50 cycles of amplification were carried out at 95°
C for 15 s followed by 1 min and 30 s at 60°C. Alu
PCR reaction mix contained 1× TaqMan Universal
Master Mix (Applied Biosystems), 50 nM primer for-
ward and 900 nM reverse primer, 100 nM TaqMan
probe and 6 μl of template low-molecular weight DNA
(100 to 250 ng total) in a volume of 20 μl. After an initial
incubation at 95°C for 10 min, 50 cycles of amplification
Table 3 Oligonucleotides used for pWPTs-GFP quantitative PCR (De Iaco 2012)
Primer name Primer sequence
Late RT pWPT J1B fwd 5′-GCATACATTATACGAAGTTATGCTGC-3′
pWPT J2 rev 5′-GCCGTGCGCGCTTCAGCAAGC-3′
2-LTR Junct2 fwd 5′-CAGTGTGGAAAATCTCTAGCAGTAC-3′
pWPT J2 rev 5′-GCCGTGCGCGCTTCAGCAAGC-3′
Alu PCR pWPT J1B fwd 5′-GCATACATTATACGAAGTTATGCTGC-3′
SB704 rev 5′-TGCTGGGATTACAGGCGTGAG-3′
MH603 probe 5′(FAM)-ACACTACTTGAAGCACTCAAGGCAAGCTTT-(TAMRA)3′
Table 4 Oligonucleotides used for NL4.3 GFP E- quantitative PCR (De Iaco, 2012 and Butler, 2001)
Primer name Primer sequence
Late RT J1 fwd 5′-ACAAGCTAGTACCAGTTGAGCCAGATAAG-3′
J2 rev 5′- GCCGTGCGCGCTTCAGCAAGC-3′
LRT-P 5′-(FAM)-CAGTGGCGCCCGAACAGGGA-(TAMRA)-3′
2-LTR MH535 5′-AACTAGGGAACCCACTGCTTAAG-3′
MH536 5′-TCCACAGATCAAGGATATCTTGTC-3′
JunctPro 5′- (FAM)-CTCTAGCAGTACTGGAAGGGCTA-(TAMRA)-3′
Alu PCR MH535 5′-AACTAGGGAACCCACTGCTTAAG-3′
SB704 rev 5′-TGCTGGGATTACAGGCGTGAG-3′
MH603 probe 5′-(FAM)-ACACTACTTGAAGCACTCAAGGCAAGCTTT-(TAMRA)-3′
Mito. DNA MH533 5′-ACCCACTCCCTCTTAGCCAATATT-3′
MH534 5′-GTAGGGCTAGGCCCACCG-3′
Mito probe 5′-(TET)-CTAGTCTTTGCCGCCTGCGAAGCA-(TAMRA)-3′
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were carried out at 95°C for 15 s followed by 1 min and
30 s at 60°C Real-Time PCR reactions were run on a
CFX96™ thermal cycler (Biorad).
Western blot
For western blot analysis 2 × 106 HEK cells and 0.5 ×
106 to 1 × 106 MDDCs were lysed in 200 μl and 50 μl
1% Triton lysis buffer (1% Triton X-100 (v/v), 50 mM
Tris–HCl, pH 7.4 and 150 mM NaCl, supplemented
with complete mini EDTA-free protease inhibitor cock-
tail tablets (Roche Applied Science)), respectively. Cells
were lysed for 10 min on ice and centrifuged for 10 min
at 14000 × g. The supernantant was transferred to a new
tube, mixed with 2× Laemmli sample buffer (62.5 mM
Tris, pH 6.8, 2% SDS, 10% glycerin, 715 mM β-mercap-
toethanol and 0.001% bromophenol blue), supplemented
with 2 mM EDTA and boiled at 100°C for 5 min. 15 μl
were loaded onto a 12% SDS-PAGE. After SDS-PAGE,
proteins were transferred onto an Immuno-Blot polyviny-
lidene fluoride (PVDF) membrane for 90 min at 110 V
constant. The following antibodies were used in this study:
anti-β-actin (Cat# M4439) and anti-GAPDH (Cat#G8795)
were from Sigma-Aldrich. Polyclonal rabbit antibodies
against MX1 (Cat# 13750-1-AP) and SAMHD1 (Cat#
12586-1-AP9) were purchased from ProteinTech Group.
The following reagents were obtained through the AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH: HIV-2 Vpx Monoclonal Antibody
(6D2.6) from Dr. John C. Kappes [70] and the Monoclonal
Antibody to HIV-1 p24 (AG3.0) from Dr. Jonathan Allan
[71]. Secondary antibodies HRP-linked donkey anti-rabbit
IgG or HRP-linked sheep anti-mouse IgG were purchased
from GE Healthcare Life Sciences. ECL or ECL Plus™
Western Blotting Detection Reagents (GE Healthcare Life
Sciences) was used to reveal HRP signal on a Fujifilm
LAS-4000 camera. Images were analyzed using the Multi-
Gauge software (Fujifilm) and GIMP (General public soft-
ware license).
Intracellular nucleotide concentration
To measure the intracellular concentration in MDDCs,
2 × 106 cells were incubated with Vpx-VLPs or nucleo-
sides for the indicated timepoints and then harvested. The
cell pellet was washed twice with PBS and the cells were
lysed by resuspending the pellet in ice cold 65% methanol
(100 μl per 1 × 106 cells) and vigorously vortexed for
2 min. The cell lysate was then incubate at 95°C for 3 min
and spun for 3 min at 14′000 rpm. The 65% methanol
solution was then transferred to a new tube and com-
pletely dried by speed vacuum centrifugation. The dNTP
pellet was store at -70°C until nucleotide measurement
assay was performed as described elsewhere [47].
Additional files
Additional file 1: Figure S1. SAMHD1 degradation timecourse. MDDCs
were stimulated or not with 100 ng/ml LPS for 24 hrs and then treated
with Vpx-VLPs. Protein samples for western blot anaylsis were collected
before Vpx-VLPs addtion (0 hrs) or 3 hrs, 9 hrs, 24 hrs and 48 hrs after
addition. Western blot for SAMHD1 and Actin as loading control is shown
(A). SAMHD1 protein levels were quantified after normalizion to the
loading control and the 0 hrs samples for either in the absence or presence
of LPS was set as 100% (B).
Additional file 2: Figure S2. SAMHD1 degradation timecourse. MDDCs
from two donors were stimulated or not with 100 ng/ml LPS for 24 hrs
and then treated with Vpx-VLPs. Protein samples for western blot anaylsis
were collected 24 hrs addition. Western blot for SAMHD1, MX1, GAPDH1
and Actin as loading control is shown (A). SAMHD1 protein levels were
quantified after normalizion to the loading control and the 0 hrs samples
for either in the absence or presence of LPS was set as 100% (B).
Nucleotides were exctracted from one sample per contidion and the
concenration of deoxyadenosine (C) and deoxythymidine triphosphates
(D) was measured.
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